Synergistic action of quercetin and genistein in human ovarian carcinoma cells

Fei Shen, George Weber

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Ovarian carcinoma is the fourth most common cause of cancer death in women and there has been a steady increase in the age-adjusted cancer death rates in the past 25 years in the US. However, patients who become cisplatin resistant respond poorly to available cytotoxic agents; therefore, discovering novel targets for ovarian carcinoma is vital. Quercetin, an anticancer agent, arrests the cell cycle at G1 and S phase boundary. Genistein, a plant flavonoid, attacks the cell cycle at G2 and/or early M phases in most carcinoma cells. Quercetin and genistein block the phosphatidylinositol conversion to IP3 signal transduction pathway mainly by inhibiting 1-phosphatidylinositol 4-kinase (PI kinase, EC 2.7.1.67) and 1-phosphatidylinositol 4-phosphate 5-kinase (PIP kinase, EC 2.7.1.68), respectively. Because each drug attacks a different phase of the cell cycle and reduces IP3 concentration by attacking different signal transduction enzymes, we tested the hypothesis that the two drugs might be synergistic in human carcinoma cells. In human ovarian carcinoma OVCAR-5 cells in growth inhibition assay, the IC50s for quercetin and genistein were (mean ± SE) 66 ± 3.0 and 32 ± 2.5 μM; in clonogenic assays they were 15 ± 1.2 and 5 ± 0.5 μM, respectively. When quercetin was added to the cultures of OVCAR-5 cells followed 8 h later by genistein, synergism was observed in growth inhibition and clonogenic assays. The synergistic action of quercetin and genistein may be of interest in clinical treatment of human ovarian carcinoma.

Original languageEnglish
Pages (from-to)597-602
Number of pages6
JournalOncology Research
Volume9
Issue number11-12
StatePublished - 1997

Fingerprint

Genistein
Quercetin
Carcinoma
Signal Transduction
Cell Cycle
Phosphotransferases
1-Phosphatidylinositol 4-Kinase
Cytotoxins
G1 Phase
Growth
Phosphatidylinositols
Cell Cycle Checkpoints
S Phase
Flavonoids
Pharmaceutical Preparations
Cell Division
Antineoplastic Agents
Cisplatin
Cause of Death
Neoplasms

Keywords

  • Genistein
  • Ovarian carcinoma
  • Quercetin
  • Signal transduction

ASJC Scopus subject areas

  • Cancer Research

Cite this

Synergistic action of quercetin and genistein in human ovarian carcinoma cells. / Shen, Fei; Weber, George.

In: Oncology Research, Vol. 9, No. 11-12, 1997, p. 597-602.

Research output: Contribution to journalArticle

Shen, Fei ; Weber, George. / Synergistic action of quercetin and genistein in human ovarian carcinoma cells. In: Oncology Research. 1997 ; Vol. 9, No. 11-12. pp. 597-602.
@article{22d596eeaf654b2c8aef0c3fdf0e65b5,
title = "Synergistic action of quercetin and genistein in human ovarian carcinoma cells",
abstract = "Ovarian carcinoma is the fourth most common cause of cancer death in women and there has been a steady increase in the age-adjusted cancer death rates in the past 25 years in the US. However, patients who become cisplatin resistant respond poorly to available cytotoxic agents; therefore, discovering novel targets for ovarian carcinoma is vital. Quercetin, an anticancer agent, arrests the cell cycle at G1 and S phase boundary. Genistein, a plant flavonoid, attacks the cell cycle at G2 and/or early M phases in most carcinoma cells. Quercetin and genistein block the phosphatidylinositol conversion to IP3 signal transduction pathway mainly by inhibiting 1-phosphatidylinositol 4-kinase (PI kinase, EC 2.7.1.67) and 1-phosphatidylinositol 4-phosphate 5-kinase (PIP kinase, EC 2.7.1.68), respectively. Because each drug attacks a different phase of the cell cycle and reduces IP3 concentration by attacking different signal transduction enzymes, we tested the hypothesis that the two drugs might be synergistic in human carcinoma cells. In human ovarian carcinoma OVCAR-5 cells in growth inhibition assay, the IC50s for quercetin and genistein were (mean ± SE) 66 ± 3.0 and 32 ± 2.5 μM; in clonogenic assays they were 15 ± 1.2 and 5 ± 0.5 μM, respectively. When quercetin was added to the cultures of OVCAR-5 cells followed 8 h later by genistein, synergism was observed in growth inhibition and clonogenic assays. The synergistic action of quercetin and genistein may be of interest in clinical treatment of human ovarian carcinoma.",
keywords = "Genistein, Ovarian carcinoma, Quercetin, Signal transduction",
author = "Fei Shen and George Weber",
year = "1997",
language = "English",
volume = "9",
pages = "597--602",
journal = "Oncology Research",
issn = "0965-0407",
publisher = "Cognizant Communication Corporation",
number = "11-12",

}

TY - JOUR

T1 - Synergistic action of quercetin and genistein in human ovarian carcinoma cells

AU - Shen, Fei

AU - Weber, George

PY - 1997

Y1 - 1997

N2 - Ovarian carcinoma is the fourth most common cause of cancer death in women and there has been a steady increase in the age-adjusted cancer death rates in the past 25 years in the US. However, patients who become cisplatin resistant respond poorly to available cytotoxic agents; therefore, discovering novel targets for ovarian carcinoma is vital. Quercetin, an anticancer agent, arrests the cell cycle at G1 and S phase boundary. Genistein, a plant flavonoid, attacks the cell cycle at G2 and/or early M phases in most carcinoma cells. Quercetin and genistein block the phosphatidylinositol conversion to IP3 signal transduction pathway mainly by inhibiting 1-phosphatidylinositol 4-kinase (PI kinase, EC 2.7.1.67) and 1-phosphatidylinositol 4-phosphate 5-kinase (PIP kinase, EC 2.7.1.68), respectively. Because each drug attacks a different phase of the cell cycle and reduces IP3 concentration by attacking different signal transduction enzymes, we tested the hypothesis that the two drugs might be synergistic in human carcinoma cells. In human ovarian carcinoma OVCAR-5 cells in growth inhibition assay, the IC50s for quercetin and genistein were (mean ± SE) 66 ± 3.0 and 32 ± 2.5 μM; in clonogenic assays they were 15 ± 1.2 and 5 ± 0.5 μM, respectively. When quercetin was added to the cultures of OVCAR-5 cells followed 8 h later by genistein, synergism was observed in growth inhibition and clonogenic assays. The synergistic action of quercetin and genistein may be of interest in clinical treatment of human ovarian carcinoma.

AB - Ovarian carcinoma is the fourth most common cause of cancer death in women and there has been a steady increase in the age-adjusted cancer death rates in the past 25 years in the US. However, patients who become cisplatin resistant respond poorly to available cytotoxic agents; therefore, discovering novel targets for ovarian carcinoma is vital. Quercetin, an anticancer agent, arrests the cell cycle at G1 and S phase boundary. Genistein, a plant flavonoid, attacks the cell cycle at G2 and/or early M phases in most carcinoma cells. Quercetin and genistein block the phosphatidylinositol conversion to IP3 signal transduction pathway mainly by inhibiting 1-phosphatidylinositol 4-kinase (PI kinase, EC 2.7.1.67) and 1-phosphatidylinositol 4-phosphate 5-kinase (PIP kinase, EC 2.7.1.68), respectively. Because each drug attacks a different phase of the cell cycle and reduces IP3 concentration by attacking different signal transduction enzymes, we tested the hypothesis that the two drugs might be synergistic in human carcinoma cells. In human ovarian carcinoma OVCAR-5 cells in growth inhibition assay, the IC50s for quercetin and genistein were (mean ± SE) 66 ± 3.0 and 32 ± 2.5 μM; in clonogenic assays they were 15 ± 1.2 and 5 ± 0.5 μM, respectively. When quercetin was added to the cultures of OVCAR-5 cells followed 8 h later by genistein, synergism was observed in growth inhibition and clonogenic assays. The synergistic action of quercetin and genistein may be of interest in clinical treatment of human ovarian carcinoma.

KW - Genistein

KW - Ovarian carcinoma

KW - Quercetin

KW - Signal transduction

UR - http://www.scopus.com/inward/record.url?scp=0031324596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031324596&partnerID=8YFLogxK

M3 - Article

C2 - 9563007

AN - SCOPUS:0031324596

VL - 9

SP - 597

EP - 602

JO - Oncology Research

JF - Oncology Research

SN - 0965-0407

IS - 11-12

ER -